Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
US11897921B2 · kind B2 · utility
0Cited by
44References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2015 |
| Grant date | Feb 13, 2024 |
| Priority date | — |
| Expiry date | Dec 9, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a fusion protein comprising a light chain region of a Clostridial neurotoxin and a heavy chain region of a Clostridial neurotoxin, where the light and heavy chain regions are linked by a disulfide bond. The fusion protein also has a single chain antibody positioned upstream of the light chain region, where the single chain antibody possesses antigen-binding activity. Also disclosed are therapeutic agents, treatment methods, propeptide fusions, isolated nucleic acid molecules, expression systems, host cells, and methods of expressing fusion proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.